232 related articles for article (PubMed ID: 34628487)
1. Evaluation of dynamic thiol/disulfide homeostasis in hereditary tyrosinemia type 1 patients.
Aktuglu Zeybek AC; Kiykim E; Neselioglu S; Iscan HZ; Zubarioglu T; Cansever MS; Erel O
Pediatr Res; 2022 Aug; 92(2):474-479. PubMed ID: 34628487
[TBL] [Abstract][Full Text] [Related]
2. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.
Bhushan S; Noble C; Balouch F; Lewindon P; Lampe G; Hodgkinson P; McGill J; Ee L
Pediatr Transplant; 2022 Nov; 26(7):e14334. PubMed ID: 35698261
[TBL] [Abstract][Full Text] [Related]
4. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood.
Rokaitė R; Čibirkaitė A; Zeleckytė V; Lazdinytė G; Dženkaitis M
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256395
[TBL] [Abstract][Full Text] [Related]
5. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
[TBL] [Abstract][Full Text] [Related]
6. Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype.
Neuckermans J; Lequeue S; Claes P; Heymans A; Hughes JH; Colemonts-Vroninks H; Marcélis L; Casimir G; Goyens P; Martens GA; Gallagher JA; Vanhaecke T; Bou-Gharios G; De Kock J
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980965
[TBL] [Abstract][Full Text] [Related]
7. Type 1 tyrosinemia in Finland: a nationwide study.
Äärelä L; Hiltunen P; Soini T; Vuorela N; Huhtala H; Nevalainen PI; Heikinheimo M; Kivelä L; Kurppa K
Orphanet J Rare Dis; 2020 Oct; 15(1):281. PubMed ID: 33046095
[TBL] [Abstract][Full Text] [Related]
8. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
[TBL] [Abstract][Full Text] [Related]
9. Hereditary Tyrosinemia Type 1 in Turkey.
Aktuglu-Zeybek AC; Kiykim E; Cansever MS
Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
[TBL] [Abstract][Full Text] [Related]
10. Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.
Couce ML; Sánchez-Pintos P; Aldámiz-Echevarría L; Vitoria I; Navas V; Martín-Hernández E; García-Volpe C; Pintos G; Peña-Quintana L; Hernández T; Gil D; Sánchez-Valverde F; Bueno M; Roca I; López-Ruzafa E; Díaz-Fernández C
Medicine (Baltimore); 2019 Sep; 98(39):e17303. PubMed ID: 31574857
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dynamic thiol/disulphide homeostasis as a novel indicator of oxidative stress in maple syrup urine disease patients under treatment.
Zubarioglu T; Kiykim E; Cansever MS; Neselioglu S; Aktuglu-Zeybek C; Erel O
Metab Brain Dis; 2017 Feb; 32(1):179-184. PubMed ID: 27535382
[TBL] [Abstract][Full Text] [Related]
12. Late Development of Hepatocellular Carcinoma in Tyrosinemia Type 1 Despite Nitisinone (NTBC) Treatment.
Almuqbil M; Knoll J; Chinsky JM
J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):e73-e75. PubMed ID: 32141999
[No Abstract] [Full Text] [Related]
13. First Scandinavian case of successful pregnancy during nitisinone treatment for type 1 tyrosinemia.
Äärelä L; Nevalainen PI; Kurppa K; Hiltunen P
J Pediatr Endocrinol Metab; 2020 May; 33(5):661-664. PubMed ID: 32238608
[TBL] [Abstract][Full Text] [Related]
14. Liver Transplantation: A Safe and Definitive Alternative to Lifelong Nitisinone for Tyrosinemia Type 1.
Menon J; Shanmugam N; Valamparampil JJ; Hakeem A; Vij M; Jalan A; Reddy MS; Rela M
Indian J Pediatr; 2022 May; 89(5):438-444. PubMed ID: 34398413
[TBL] [Abstract][Full Text] [Related]
15. Thiol/disulfide homeostasis as a marker of oxidative stress in rosacea: a controlled spectrophotometric study.
Sener S; Akbas A; Kilinc F; Baran P; Erel O; Aktas A
Cutan Ocul Toxicol; 2019 Mar; 38(1):55-58. PubMed ID: 30173569
[TBL] [Abstract][Full Text] [Related]
16. Thiol/disulfide homeostasis as a novel indicator of oxidative stress in children with simple febrile seizures.
Elmas B; Erel Ö; Ersavaş D; Yürümez Y
Neurol Sci; 2017 Nov; 38(11):1969-1975. PubMed ID: 28808794
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of dynamic thiol-disulfide homeostasis in very low-birth-weighted preterms.
Unal S; Ulubas Isik D; Bas AY; Erol S; Arifoglu İ; Alisik M; Erel O; Demirel N
J Matern Fetal Neonatal Med; 2019 Apr; 32(7):1111-1116. PubMed ID: 29092682
[TBL] [Abstract][Full Text] [Related]
18. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
Luijerink MC; Jacobs SM; van Beurden EA; Koornneef LP; Klomp LW; Berger R; van den Berg IE
J Hepatol; 2003 Dec; 39(6):901-9. PubMed ID: 14642604
[TBL] [Abstract][Full Text] [Related]
19. Novel Assay Assessment of Oxidative Stress Biomarkers in Patients with Keratoconus: Thiol-Disulfide Homeostasis.
Gulpamuk B; Koç M; Karatepe MS; Yildiz A; Erel O; Neselioglu S; Yilmazbas P
Curr Eye Res; 2017 Sep; 42(9):1215-1219. PubMed ID: 28557572
[TBL] [Abstract][Full Text] [Related]
20. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
Prescrire Int; 2007 Apr; 16(88):56-8. PubMed ID: 17458044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
